Zentalis Q3 cash $421.7M, ZN-c3 dose optimization extends USC trial; Cyclin E biomarker strategy set

Zentalis Pharmaceuticals, Inc.

Cash $421.7M as of Sep 30, 2022; runway into Q1 2025.
R&D expenses $42.2M (down 22% YoY); G&A $12.0M (up 35% YoY).
ZN-c3 dose optimization extends USC trial timeline; update expected H1 2023.
Cyclin E amplification/overexpression selected as biomarker for ZN-c3 monotherapy in ovarian cancer.
Appointed new CMO (Carrie Brownstein), CSO (Kevin Bunker), CTO (Mark Lackner); added board member Jan Skvarka.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zentalis Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-22-000199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.